Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer

Next Previous
X
Search
Trial Profile

A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 21 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Margetuximab (Primary) ; Retifanlimab (Primary) ; Tebotelimab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin; Trastuzumab
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MAHOGANY
  • Sponsors MacroGenics

    • Most Recent Events

    • 13 May 2024 Planned End Date changed from 1 Mar 2024 to 1 Jun 2025.
    • 12 Mar 2024 This trial has been completed in Italy, according to European Clinical Trials Database record.
    • 22 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top